| Jonathan A Snellgrove, DPM | |
|
1650 S 41st St, Manitowoc, WI 54220-7316 | |
| (920) 320-5251 | |
| (920) 682-2006 |
| Full Name | Jonathan A Snellgrove |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 24 Years |
| Location | 1650 S 41st St, Manitowoc, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548260060 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | PO 3012 (Florida) | Secondary |
| 213E00000X | Podiatrist | 1428 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pensacola Podiatry, P.a. | 5698896298 | 3 |
News Archive
The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.
The "Blueprint for an AIDS-free Generation," released on Thursday by U.S. Secretary of State Hillary Clinton, "shows that upfront investments to support the rapid scale-up of lifesaving AIDS treatment will yield significant savings - of both lives and dollars - in the near future," Archbishop Desmond Tutu, archbishop emeritus of Cape Town, South Africa, writes in the Huffington Post's "Impact" blog.
About 90 percent of cancer deaths are caused by tumors that have spread from their original locations. This process, known as metastasis, requires cancer cells to break loose from their neighbors and from the supportive scaffold that gives tissues their structure.
A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics' CRISPR/Cas9 patent portfolio.
› Verified 2 days ago
| Provider Name | Pensacola Podiatry, P.a. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1790960508 PECOS PAC ID: 5698896298 Enrollment ID: O20120605000092 |
News Archive
The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.
The "Blueprint for an AIDS-free Generation," released on Thursday by U.S. Secretary of State Hillary Clinton, "shows that upfront investments to support the rapid scale-up of lifesaving AIDS treatment will yield significant savings - of both lives and dollars - in the near future," Archbishop Desmond Tutu, archbishop emeritus of Cape Town, South Africa, writes in the Huffington Post's "Impact" blog.
About 90 percent of cancer deaths are caused by tumors that have spread from their original locations. This process, known as metastasis, requires cancer cells to break loose from their neighbors and from the supportive scaffold that gives tissues their structure.
A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics' CRISPR/Cas9 patent portfolio.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan A Snellgrove, DPM Po Box 2290, Manitowoc, WI 54221-2290 Ph: (920) 320-2591 | Jonathan A Snellgrove, DPM 1650 S 41st St, Manitowoc, WI 54220-7316 Ph: (920) 320-5251 |
News Archive
The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.
The "Blueprint for an AIDS-free Generation," released on Thursday by U.S. Secretary of State Hillary Clinton, "shows that upfront investments to support the rapid scale-up of lifesaving AIDS treatment will yield significant savings - of both lives and dollars - in the near future," Archbishop Desmond Tutu, archbishop emeritus of Cape Town, South Africa, writes in the Huffington Post's "Impact" blog.
About 90 percent of cancer deaths are caused by tumors that have spread from their original locations. This process, known as metastasis, requires cancer cells to break loose from their neighbors and from the supportive scaffold that gives tissues their structure.
A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics' CRISPR/Cas9 patent portfolio.
› Verified 2 days ago
Dr. Jason G De Vries, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1111 Bayshore Dr, Manitowoc, WI 54220 Phone: 920-682-6376 Fax: 920-652-0115 |